Paris: Sanofi-Aventis, French pharmaceutical group has annunciated that the U.S. health officials have approved another application of its anti-cancer drug ‘Taxotere.’
The company said that the drug has been sanctioned to treat locally advanced head and neck cancer before chemo-radiotherapy and surgical treatment.
The approval is based on the outcomes of a phase III clinical examination, which showed that adding up Taxotere to typical induction chemotherapy resulted in a more than three year betterment in patient endurance rate.
Rockville: The FDA will assemble a public trial by next month to think about formalizing a dispensing g
